Loss of ARID1A expression is associated with worse survival and reduced tumor infiltrating lymphocytes in advanced clear cell renal cell carcinoma
Low ARID1A expression (protein and mRNA) is a marker of poor prognosis in ccRCC, and is associated with shorter survival and reduced TILs, but immune cells linked to ICI response are increased offering an immune advantage to ARID1A<sup>Low</sup> patients who receive ICI therapy. ARID1A IHC provides comparable results to bulk mRNA analysis, suggesting that it can be reliably used to explore ARID1A as a potential ICI biomarker in ccRCC.
Authors
- Ekaterini Boleti
- Raj Patel (ORCID: https://orcid.org/0000-0003-3093-8502)
- Axel Bex (ORCID: https://orcid.org/0000-0002-8499-2662)
- Faiz Mumtaz (ORCID: https://orcid.org/0000-0002-0211-3936)
- Maxine G B Tran (ORCID: https://orcid.org/0000-0002-6034-4433)
- Mohamed Ashraf Mansour
- Soha El-Sheikh
Institutions
- Royal Free London NHS Foundation Trust (GB)
- University of Cambridge (GB)
- The Royal Free Hospital (GB)
- Cancer Research UK (GB)
- The Netherlands Cancer Institute (NL)
- CRUK Lung Cancer Centre of Excellence (GB)
- Roland Hill (United Kingdom) (GB)
- University College London (GB)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1007/s12094-025-04166-8
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Royal Free London NHS Foundation Trust
- University College London
- University College London Hospitals NHS Foundation Trust